Title
Category
Credits
Event date
Cost
Diagnosis and Pharmacotherapy of Bipolar Depression in Pediatric Patients
  • Bipolar Disorder
  • Depression
  • Child and Adolescent Psychiatry
  • Diagnostic Tools
  • Psychopharmacology
  • Side Effects
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
What are the evidence-based pharmacologic treatment approaches for pediatric patients with bipolar depression?
Diagnosis and Pharmacotherapy of Bipolar Depression in Adults
  • Bipolar Disorder
  • Depression
  • Diagnostic Tools
  • Psychopharmacology
  • Side Effects
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Join Dr Goldberg as he reviews factors that impact the diagnosis of bipolar disorder and current treatments for bipolar depression in adults.
Postpartum Depression and Psychosis and Subsequent Severe Mental Illnesses in Mothers and Neurodevelopmental Disorders in Children: A Nationwide Study
  • Bipolar Disorder
  • Depression
  • Attention-Deficit/Hyperactivity Disorder
  • Autism Spectrum Disorders
  • Child and Adolescent Psychiatry
  • Psychotic Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Women’s Mental Health
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Is there an association between postpartum depression or psychosis and subsequent disorders in either the mother or the child who is exposed to postpartum maternal illness?
Measurement-Based Diagnosis and Treatment for Tardive Dyskinesia
  • Bipolar Disorder
  • Depression
  • Antipsychotics
  • Diagnostic Tools
  • Schizophrenia/ Schizoaffective Disorders
  • Tardive Dyskinesia
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Experts offer a review of the fundamentals of diagnosing and treating tardive dyskinesia.
The Efficacy of Measurement-Based Care for Depressive Disorders: Systematic Review and Meta-Analysis of Randomized Controlled Trials
  • Depression
  • Delivery of Care
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
For patients with depressive disorders treated with pharmacotherapy, measurement-based care is effective in decreasing symptom severity, promoting remission, and improving medication adherence.
Individualizing Treatment Selection for Pediatric and Adult Patients With Bipolar Depression
  • Bipolar Disorder
  • Depression
  • Antidepressants
  • Antipsychotics
  • Child and Adolescent Psychiatry
  • Diagnostic Tools
  • Mood Disorders
  • Patient/Physician Communication
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Drs Findling and Goldberg offer expertise on the diagnosis and treatment of bipolar disorder in patients of all ages.
Remission and Treatment Augmentation of Depression in the United States
  • Depression
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Closer monitoring of symptoms through measurement-based care and setting symptom remission as a goal can help improve outcomes for adults with depression.
Treatment-Resistant Mood Disorders in LGBTQ People: A Retrospective Study of Clinical Features and Response to Electroconvulsive Therapy
  • Mood Disorders
  • Depression
  • Electroconvulsive Therapy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
In this chart review, LGBTQ people with treatment-resistant mood disorders had clinical features linked to worse outcomes, but their improvement with ECT was similar to that seen in non-LGBTQ patients.
Screening and Accurate Diagnosis of Patients With Bipolar Disorder Type I and Type II
  • Bipolar Disorder
  • Bipolar Depression
  • Depression
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Drs Goldberg, Swartz, and DelBello discuss the spectrum of bipolar disorder, from major depressive disorder to bipolar I, and assessment strategies for establishing accurate diagnoses, including age, gender, signs and symptoms, and comorbidities to facilitate appropriate treatments and improve patient outcomes.
Treatment Options for Bipolar I and Bipolar II Disorder
  • Bipolar Disorder
  • Bipolar Depression
  • Depression
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
As novel agents join the treatment landscape for bipolar I and bipolar II disorder and new data emerge on existing therapeutics, clinicians need education on the latest evidence of the safety and efficacy profiles of existing and emerging treatments for bipolar I and bipolar II disorder. Join Drs Goldberg, DelBello, and Swartz in examining how to integrate this information into clinical practice and provide efficacious and tolerable treatment for patients with bipolar I and bipolar II disorder.

Pages